Comparative Pharmacology
Head-to-head clinical analysis: NEPHROFLOW versus TECHNESCAN HIDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEPHROFLOW versus TECHNESCAN HIDA.
NEPHROFLOW vs TECHNESCAN HIDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NEPHROFLOW is a vasodilator that increases renal blood flow by selectively dilating afferent arterioles, leading to enhanced glomerular filtration rate (GFR). It also inhibits sodium reabsorption in the proximal tubule, promoting diuresis.
Technetium Tc-99m mebrofenin is a radiopharmaceutical that, after intravenous administration, is taken up by hepatocytes via organic anion transporting polypeptides (OATPs) and excreted into the bile canaliculi via multidrug resistance-associated protein 2 (MRP2). It allows scintigraphic evaluation of hepatobiliary function by emitting gamma radiation detectable by a gamma camera.
NEPHROFLOW (Ioversol) 350 mg iodine/mL: 1 mL/kg intravenously up to 150 mL maximum for contrast imaging.
5 mCi (185 MBq) administered intravenously as a single dose for hepatobiliary imaging.
None Documented
None Documented
4.2 hours (terminal) in normal renal function; prolongs in CKD.
Terminal elimination half-life is approximately 1.5 hours (range 1-2 hours) in patients with normal hepatic function. In patients with hepatic impairment, half-life may be prolonged up to 4-6 hours.
Primarily renal (85% unchanged); 15% biliary/fecal. In renal impairment, half-life doubles.
Primarily biliary excretion: 85-90% of administered dose is excreted into bile via the hepatobiliary system within 2 hours, with minimal renal elimination (<5%) and fecal excretion accounting for <2%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical